<p>Oppenheimer 在周一向投资者发布的报告中开始覆盖 Tarsus Pharmaceuticals (NASDAQ:TARS - 获取免费报告) 的股票。该券商对该股票设定了 “跑赢大盘” 的评级，并给出了 75.00 美元的目标价。Oppenheimer 的目标价表明该公司股价有潜在的 76.10% 上涨空间。</p>
<p>获取 <strong>Tarsus Pharmaceuticals</strong> 的提醒：</p>
<p>其他股票研究分析师最近也对该股票发布了报告。巴克莱将 Tarsus Pharmaceuticals 的股票目标价从 62.00 美元下调至 60.00 美元，并在 2 月 26 日的研究报告中对该股票设定了 “增持” 评级。高盛将 Tarsus Pharmaceuticals 的股票目标价从 46.00 美元上调至 51.00 美元，并在 5 月 5 日的研究报告中给予该股票 “中性” 评级。华尔街 Zen 在 5 月 22 日的研究报告中将 Tarsus Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”。古根海姆在 5 月 2 日的研究报告中将 Tarsus Pharmaceuticals 的股票目标价从 78.00 美元上调至 84.00 美元，并给予该公司 “买入” 评级。最后，HC Wainwright 在 5 月 27 日的研究报告中将 Tarsus Pharmaceuticals 的股票评级提升至 “买入”，并设定了 72.00 美元的目标价。两位研究分析师对该股票给予了持有评级，五位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 66.67 美元。</p>
<p><strong>阅读我们关于 TARS 的最新报告</strong></p>
<h2>Tarsus Pharmaceuticals 股价表现</h2>
<p>周一，TARS 股价下跌 0.36 美元，达到 42.59 美元。该公司股票交易量为 43,739 股，而其平均交易量为 699,781 股。该股票的市值为 17.9 亿美元，市盈率为 -11.21，贝塔值为 0.94。Tarsus Pharmaceuticals 的 12 个月最低价为 20.08 美元，最高价为 57.28 美元。该股票的 50 日移动平均价格为 46.93 美元，200 日移动平均价格为 48.96 美元。该公司的债务与股本比率为 0.30，流动比率为 5.42，速动比率为 5.38。</p>
<p>Tarsus Pharmaceuticals (NASDAQ:TARS - 获取免费报告) 最近在 5 月 1 日发布了其财报。该公司报告本季度每股收益为 -0.64 美元，超出市场共识预期的 -0.69 美元 0.05 美元。该公司本季度的收入为 7834 万美元，而分析师预期为 7250 万美元。Tarsus Pharmaceuticals 的净利润率为 -103.64%，股本回报率为 -55.86%。卖方分析师预计 Tarsus Pharmaceuticals 本年度每股收益将为 -3.17 美元。</p>
<h2>Tarsus Pharmaceuticals 的内部买卖</h2>
<p>在其他消息中，首席执行官 Bobak R. Azamian 于 3 月 18 日在一笔交易中出售了 7,131 股该股票。股票以平均价格 46.29 美元出售，总价值为 330,093.99 美元。出售完成后，首席执行官现在拥有 70,720 股公司股票，价值 3,273,628.80 美元。这代表其持股比例减少了 9.16%。该交易已在证券交易委员会的法律文件中披露，相关信息可在此链接查看。此外，首席法律顾问 Bryan Wahl 于 3 月 20 日在一笔交易中出售了 3,084 股该公司的股票。该股票以平均价格 50.11 美元出售，总交易额为 154,539.24 美元。交易完成后，首席法律顾问现在直接拥有 51,712 股公司股票，价值约 2,591,288.32 美元。这代表其持股比例减少了 5.63%。该交易的披露信息可在此处找到。内部人士在上个季度出售了价值 1,581,173 美元的 32,542 股公司股票。公司内部人士持有 8.25% 的公司股票。</p>
<h2>对 Tarsus Pharmaceuticals 的对冲基金看法</h2>
<p>对冲基金最近对该公司的持仓进行了调整。Crowley Wealth Management Inc. 在第四季度收购了 Tarsus Pharmaceuticals 的新股份，价值约 25,000 美元。GF Fund Management CO. LTD. 在第四季度收购了 Tarsus Pharmaceuticals 的新股份，价值 44,000 美元。Amalgamated Bank 在第一季度将其在 Tarsus Pharmaceuticals 的股份增加了 30.1%。Amalgamated Bank 目前拥有 1,274 股公司股票，价值 65,000 美元，此前在上个季度又购买了 295 股。Quarry LP 在第四季度收购了 Tarsus Pharmaceuticals 的新股份，价值约 166,000 美元。最后，AlphaQuest LLC 在第一季度收购了 Tarsus Pharmaceuticals 的新股份，价值约 189,000 美元。机构投资者和对冲基金持有公司 90.01% 的股票。</p>
<h2>关于 Tarsus Pharmaceuticals</h2>
<p>(获取免费报告)</p>
<p>Tarsus Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司，专注于在美国开发和商业化新型眼科治疗候选药物。该公司的主要产品候选药物是 XDEMVY，一种用于治疗由蠕形螨感染引起的睑缘炎的新型治疗药物，以及用于治疗睑板腺疾病。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Tarsus Pharmaceuticals</li>
<li>制造业股票投资</li>
<li>在 Okta 中买入，前景没有问题</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>尽管亚马逊交易存在担忧，分析师对 Marvell 股票持乐观态度</li>
<li>纳斯达克证券交易所是什么？</li>
<li>你可能错过的 3 只高风险高回报的黄金 ETF</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Tarsus Pharmaceuticals 吗？</h2>
<p>在考虑 Tarsus Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Tarsus Pharmaceuticals 并不在名单上。</p>
<p>虽然 Tarsus Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TARS

<p>Oppenheimer 已经开始对 Tarsus Pharmaceuticals (NASDAQ:TARS) 进行覆盖，给予 “跑赢大盘” 的评级，并设定目标价为 75.00 美元，意味着相较于其前一交易日收盘价有 76.10% 的潜在上涨空间。其他分析师的意见各不相同，巴克莱将其目标价下调至 60.00 美元，而高盛则将其上调至 51.00 美元。该股票目前的共识评级为 “适度买入”，平均目标价为 66.67 美元。Tarsus 在上个季度报告的收入为 7834 万美元，超出预期，市值为 17.9 亿美元</p>

<p>Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) in a note issued to investors on Monday. The brokerage set an &#34;outperform&#34; rating and a $75.00 price target on the stock. Oppenheimer's target price indicates a potential upside of 76.10% from the company's previous close.</p>
<div class="lb-trans"><p>Oppenheimer 在周一向投资者发布的报告中开始覆盖 Tarsus Pharmaceuticals (NASDAQ:TARS - 获取免费报告) 的股票。该券商对该股票设定了 “跑赢大盘” 的评级，并给出了 75.00 美元的目标价。Oppenheimer 的目标价表明该公司股价有潜在的 76.10% 上涨空间。</p>
</div><p>Get <strong>Tarsus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tarsus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Other equities research analysts also recently issued reports about the stock. Barclays reduced their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an &#34;overweight&#34; rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a &#34;neutral&#34; rating in a research note on Monday, May 5th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, May 22nd. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, May 2nd. Finally, HC Wainwright raised shares of Tarsus Pharmaceuticals to a &#34;buy&#34; rating and set a $72.00 price objective on the stock in a research report on Tuesday, May 27th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $66.67.</p>
<div class="lb-trans"><p>其他股票研究分析师最近也对该股票发布了报告。巴克莱将 Tarsus Pharmaceuticals 的股票目标价从 62.00 美元下调至 60.00 美元，并在 2 月 26 日的研究报告中对该股票设定了 “增持” 评级。高盛将 Tarsus Pharmaceuticals 的股票目标价从 46.00 美元上调至 51.00 美元，并在 5 月 5 日的研究报告中给予该股票 “中性” 评级。华尔街 Zen 在 5 月 22 日的研究报告中将 Tarsus Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”。古根海姆在 5 月 2 日的研究报告中将 Tarsus Pharmaceuticals 的股票目标价从 78.00 美元上调至 84.00 美元，并给予该公司 “买入” 评级。最后，HC Wainwright 在 5 月 27 日的研究报告中将 Tarsus Pharmaceuticals 的股票评级提升至 “买入”，并设定了 72.00 美元的目标价。两位研究分析师对该股票给予了持有评级，五位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 66.67 美元。</p>
</div><p><strong>Read Our Latest Report on TARS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 TARS 的最新报告</strong></p>
</div><h2>Tarsus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 股价表现</h2>
</div><p>TARS traded down $0.36 on Monday, reaching $42.59. 43,739 shares of the company's stock were exchanged, compared to its average volume of 699,781. The stock has a market cap of $1.79 billion, a PE ratio of -11.21 and a beta of 0.94. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The stock's fifty day moving average price is $46.93 and its 200-day moving average price is $48.96. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.</p>
<div class="lb-trans"><p>周一，TARS 股价下跌 0.36 美元，达到 42.59 美元。该公司股票交易量为 43,739 股，而其平均交易量为 699,781 股。该股票的市值为 17.9 亿美元，市盈率为 -11.21，贝塔值为 0.94。Tarsus Pharmaceuticals 的 12 个月最低价为 20.08 美元，最高价为 57.28 美元。该股票的 50 日移动平均价格为 46.93 美元，200 日移动平均价格为 48.96 美元。该公司的债务与股本比率为 0.30，流动比率为 5.42，速动比率为 5.38。</p>
</div><p>Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. Sell-side analysts expect that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.</p>
<div class="lb-trans"><p>Tarsus Pharmaceuticals (NASDAQ:TARS - 获取免费报告) 最近在 5 月 1 日发布了其财报。该公司报告本季度每股收益为 -0.64 美元，超出市场共识预期的 -0.69 美元 0.05 美元。该公司本季度的收入为 7834 万美元，而分析师预期为 7250 万美元。Tarsus Pharmaceuticals 的净利润率为 -103.64%，股本回报率为 -55.86%。卖方分析师预计 Tarsus Pharmaceuticals 本年度每股收益将为 -3.17 美元。</p>
</div><h2>Insider Buying and Selling at Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 的内部买卖</h2>
</div><p>In other news, CEO Bobak R. Azamian sold 7,131 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the sale, the chief executive officer now owns 70,720 shares of the company's stock, valued at $3,273,628.80. This represents a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, General Counsel Bryan Wahl sold 3,084 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24. Following the transaction, the general counsel now directly owns 51,712 shares of the company's stock, valued at approximately $2,591,288.32. This represents a 5.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock valued at $1,581,173 over the last quarter. Corporate insiders own 8.25% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Bobak R. Azamian 于 3 月 18 日在一笔交易中出售了 7,131 股该股票。股票以平均价格 46.29 美元出售，总价值为 330,093.99 美元。出售完成后，首席执行官现在拥有 70,720 股公司股票，价值 3,273,628.80 美元。这代表其持股比例减少了 9.16%。该交易已在证券交易委员会的法律文件中披露，相关信息可在此链接查看。此外，首席法律顾问 Bryan Wahl 于 3 月 20 日在一笔交易中出售了 3,084 股该公司的股票。该股票以平均价格 50.11 美元出售，总交易额为 154,539.24 美元。交易完成后，首席法律顾问现在直接拥有 51,712 股公司股票，价值约 2,591,288.32 美元。这代表其持股比例减少了 5.63%。该交易的披露信息可在此处找到。内部人士在上个季度出售了价值 1,581,173 美元的 32,542 股公司股票。公司内部人士持有 8.25% 的公司股票。</p>
</div><h2>Hedge Funds Weigh In On Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Tarsus Pharmaceuticals 的对冲基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the business. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $44,000. Amalgamated Bank boosted its stake in shares of Tarsus Pharmaceuticals by 30.1% in the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock valued at $65,000 after purchasing an additional 295 shares in the last quarter. Quarry LP acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $166,000. Finally, AlphaQuest LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 1st quarter valued at approximately $189,000. Institutional investors and hedge funds own 90.01% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。Crowley Wealth Management Inc. 在第四季度收购了 Tarsus Pharmaceuticals 的新股份，价值约 25,000 美元。GF Fund Management CO. LTD. 在第四季度收购了 Tarsus Pharmaceuticals 的新股份，价值 44,000 美元。Amalgamated Bank 在第一季度将其在 Tarsus Pharmaceuticals 的股份增加了 30.1%。Amalgamated Bank 目前拥有 1,274 股公司股票，价值 65,000 美元，此前在上个季度又购买了 295 股。Quarry LP 在第四季度收购了 Tarsus Pharmaceuticals 的新股份，价值约 166,000 美元。最后，AlphaQuest LLC 在第一季度收购了 Tarsus Pharmaceuticals 的新股份，价值约 189,000 美元。机构投资者和对冲基金持有公司 90.01% 的股票。</p>
</div><h2>About Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Tarsus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.</p>
<div class="lb-trans"><p>Tarsus Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司，专注于在美国开发和商业化新型眼科治疗候选药物。该公司的主要产品候选药物是 XDEMVY，一种用于治疗由蠕形螨感染引起的睑缘炎的新型治疗药物，以及用于治疗睑板腺疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Tarsus Pharmaceuticals</li>
<li>Manufacturing Stocks Investing</li>
<li>Buy The Dip in Okta, There’s Nothing Wrong With the Outlook</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>3 High-Risk, High-Reward Gold ETFs You May Be Missing</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Tarsus Pharmaceuticals</li>
<li>制造业股票投资</li>
<li>在 Okta 中买入，前景没有问题</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>尽管亚马逊交易存在担忧，分析师对 Marvell 股票持乐观态度</li>
<li>纳斯达克证券交易所是什么？</li>
<li>你可能错过的 3 只高风险高回报的黄金 ETF</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TARS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tarsus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tarsus Pharmaceuticals 吗？</h2>
</div><p>Before you consider Tarsus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tarsus Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Tarsus Pharmaceuticals 并不在名单上。</p>
</div><p>While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tarsus Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Oppenheimer

Tarsus Pharmaceuticals（NASDAQ:TARS）现已被 Oppenheimer 纳入研究覆盖范围